Cargando…
Adverse Events Related to Tirzepatide
CONTEXT: Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved by the US Food and Drug Administration in May 2022 for patients with type 2 diabetes mellitus (T2DM). OBJECTIVE: We aimed to determine the rates of individua...
Autores principales: | Mishra, Rahul, Raj, Rishi, Elshimy, Ghada, Zapata, Isain, Kannan, Lakshmi, Majety, Priyanka, Edem, Dinesh, Correa, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915969/ https://www.ncbi.nlm.nih.gov/pubmed/36789109 http://dx.doi.org/10.1210/jendso/bvad016 |
Ejemplares similares
-
Case report: SARS-CoV-2 infection as a trigger for diabetic ketoacidosis and newly detected pancreatic autoantibodies
por: Mishra, Rahul, et al.
Publicado: (2022) -
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
por: Sattar, Naveed, et al.
Publicado: (2022) -
Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017) -
Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022) -
A Systematic Review and Meta-Analysis of Immune-Related Adverse
Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)